Vimarsana
Biggest News Aggregation in the World

Results Through Week News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Results Through Week. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Results Through Week Today - Breaking & Trending Today

AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis - Vimarsana News

AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Published: October 11, 2023

Three ongoing, randomized, double-blind, multicenter Phase 3 studies demonstrated the long-term efficacy and safety profile of RINVOQ® in treating moderate to severe atopic dermatitis based on...

Source: marketscreener.com
Related Topics:
United StatesMudra KapoorJ Clin DermatolExchange CommissionAbbvie LtdEuropean Academy Of DermatologyEuropean AcademyEmergent Adverse EventsGlobal AssessmentAtopic DermatitisAllergan AestheticsPrivate Securities Litigation Reform ActQuarterly ReportsUpadacitinib ThroughModerate To Severe Atopic DermatitisClinical TrialGlobal EpidemiologyAnn Nutr MetabRev Dis PrimersAdolescents With Uncontrolled ModerateSevere Atopic DermatitisTerm EfficacyResults Through WeekLabel Extension TrialHealthcare Claims Data
New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis - Vimarsana News

New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis

Published: October 24, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with...

Source: prnewswire.com
Related Topics:
United StatesSpring HouseBritish ColumbiaCraig StoltzBurrillb CrohnBrucee SandsJan WehkampAmerican College Of Gastroenterology Annual MeetingCrohn Colitis FoundationJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican College Of GastroenterologyJapan PharmaceuticalsNone Of The Janssen Pharmaceutical CompaniesNational Institutes Of HealthExchange CommissionIcahn School Of Medicine At Mount SinaiCompanies Of JohnsonEuropean Medicines AgencyDevices AgencyCanadian Agency For Drugs Technologies In HealthCrohn Colitis Foundation Of AmericaGastroenterology Annual MeetingAnnual Scientific Meeting
Johnson & Johnson : Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38 - Vimarsana News

Johnson & Johnson : Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38

Published: October 10, 2022

The rate of clinical remission was 47.9 percent in patients who received combination induction therapy with guselkumab and golimumab compared with either treatment alone at 38 weeks1 ... | October 10, 2022

Source: marketscreener.com
Related Topics:
United StatesSpring HouseCraig StoltzBrucee SandsNone Of The Janssen Pharmaceutical CompaniesCrohn Colitis FoundationSteering CommitteeJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonExchange CommissionIcahn School Of Medicine At Mount SinaiCompanies Of JohnsonColitis OrganisationCrohn Colitis Foundation Of AmericaUnited European GastroenterologyMount SinaiIcahn SchoolPrescribing InformationMedication GuideMississippi River ValleysPharmaceutical CompaniesInfectious DiseasesPrivate Securities Litigation Reform ActJanssen Research
New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years - Vimarsana News

New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years

Published: June 1, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with...

Source: prnewswire.com
Related Topics:
United StatesUniversity Of WashingtonSpring HouseBritish ColumbiaDonvitot CreakyjointsTerence RooneyPhilip MeaseBridget KimmelJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonSwedish Medical Center ProvidenceNational Psoriasis FoundationNone Of The Janssen Pharmaceutical CompaniesForm Health Survey Physical Component SummaryEuropean CongressJoseph HealthDrug AdministrationHealth Assessment QuestionnaireGuselkumab Provides Sustained Improvements In HealthExchange CommissionCompanies Of JohnsonGroup For ResearchSwedish MedicalEfficacy Across Joint
Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab and Golimumab Combination Therapy Versus Either Monotherapy Alone - Vimarsana News

Results of Novel Clinical Study Show Adults with Moderately to Severely Active Ulcerative Colitis Achieved Higher Rates of Clinical Response, Clinical Remission, and Endoscopic Improvement at 12 Weeks with Guselkumab and Golimumab Combination Therapy Versus Either Monotherapy Alone

Published: February 19, 2022

SPRING HOUSE, Pa., Feb. 19, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a Phase 2a clinical trial that showed the combination of

Source: wtva.com
Related Topics:
United StatesSpring HouseBritish ColumbiaBrucee SandsJan WehkampBridget KimmelNone Of The Janssen Pharmaceutical CompaniesCrohn Colitis FoundationJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonExchange CommissionHenryd Janowitz Division Of GastroenterologyIcahn School Of Medicine At Mount SinaiCompanies Of JohnsonColitis OrganisationEuropean CrohnIcahn SchoolMount SinaiMount Sinai HospitalVice PresidentGastroenterology Disease Area LeaderJanssen ResearchPrescribing InformationMedication Guide